nach oben

Clinical Neuroradiology

Erschienen in:

26.01.2024 | Review Article

Artificial Intelligence Imaging for Predicting High-risk Molecular Markers of Gliomas

verfasst von: Qian Liang, Hui Jing, Yingbo Shao, Yinhua Wang, Hui Zhang

Erschienen in: Clinical Neuroradiology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Gliomas, the most prevalent primary malignant tumors of the central nervous system, present significant challenges in diagnosis and prognosis. The fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System (WHO CNS5) published in 2021, has emphasized the role of high-risk molecular markers in gliomas. These markers are crucial for enhancing glioma grading and influencing survival and prognosis. Noninvasive prediction of these high-risk molecular markers is vital. Genetic testing after biopsy, the current standard for determining molecular type, is invasive and time-consuming. Magnetic resonance imaging (MRI) offers a non-invasive alternative, providing structural and functional insights into gliomas. Advanced MRI methods can potentially reflect the pathological characteristics associated with glioma molecular markers; however, they struggle to fully represent gliomas’ high heterogeneity. Artificial intelligence (AI) imaging, capable of processing vast medical image datasets, can extract critical molecular information. AI imaging thus emerges as a noninvasive and efficient method for identifying high-risk molecular markers in gliomas, a recent focus of research. This review presents a comprehensive analysis of AI imaging’s role in predicting glioma high-risk molecular markers, highlighting challenges and future directions.

Xu H, Zhang A, Han X, Li Y, Zhang Z, Song L, et al. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas. Cancer Immunol Immunother. 2022;71(3):645–60. CrossRefPubMed

Gao M, Huang S, Pan X, Liao X, Yang R, Liu J. Machine Learning-Based Radiomics Predicting Tumor Grades and Expression of Multiple Pathologic Biomarkers in Gliomas. Front Oncol. 2020;10:1676. https://doi.org/10.3389/fonc.2020.01676.CrossRefPubMedPubMedCentral

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–20.>CrossRefPubMed

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–51. https://doi.org/10.1093/neuonc/noab106.CrossRefPubMedPubMedCentral

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2020;18(3):170–86.CrossRefPubMedPubMedCentral

Yang X, Qin D, Zhang H. Advances in deep learning-based radiomics for precision diagnosis and treatment of glioma. Chin J Radiol. 2023;57(08):931–5.

Lam LHT, Do DT, Diep DTN, Nguyet DLN, Truong QD, Tri TT, et al. Molecular subtype classification of low-grade gliomas using magnetic resonance imaging-based radiomics and machine learning. Nmr Biomed. 2022; https://doi.org/10.1002/nbm.4792.CrossRefPubMed

Zhuge Y, Ning H, Mathen P, Cheng JY, Krauze AV, Camphausen K, et al. Automated glioma grading on conventional MRI images using deep convolutional neural networks. Med Phys. 2020;47(7):3044–53. https://doi.org/10.1002/mp.14168.CrossRefPubMed

Xing Z, Yang X, She D, Lin Y, Zhang Y, Cao D. Noninvasive Assessment of IDH Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging. AJNR Am J Neuroradiol. 2017;38(6):1138–44. https://doi.org/10.3174/ajnr.A5171.CrossRefPubMedPubMedCentral

10.

Grech-Sollars M, Ordidge KL, Vaqas B, Davies C, Vaja V, Honeyfield L, et al. Imaging and Tissue Biomarkers of Choline Metabolism in Diffuse Adult Glioma: 18F-Fluoromethylcholine PET/CT, Magnetic Resonance Spectroscopy, and Choline Kinase alpha. Cancers (basel). 2019; https://doi.org/10.3390/cancers11121969.CrossRefPubMed

11.

Ivanidze J, Lum M, Pisapia D, Magge R, Ramakrishna R, Kovanlikaya I, et al. MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma. J Neuroimaging. 2019;29(3):357–63. https://doi.org/10.1111/jon.12596.CrossRefPubMed

12.

Ahn SS, An C, Park YW, Han K, Chang JH, Kim SH, et al. Identification of magnetic resonance imaging features for the prediction of molecular profiles of newly diagnosed glioblastoma. J Neurooncol. 2021;154(1):83–92.CrossRefPubMed

13.

Hu LS, D’Angelo F, Weiskittel TM, Caruso FP, Fortin Ensign SP, Blomquist MR, et al. Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures. Nat Commun. 2023;

14.

Ni J, Wang P. Present and future: artificial intelligence in medical imaging. Natl Med J China. 2021;101(7):455–7.

15.

Park YW, Kim S, Park CJ, Ahn SS, Han K, Kang SG, et al. Adding radiomics to the. Radiol, Vol. 2022. updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status. Eur: WHO; 2021.

16.

Mayerhoefer ME, Materka A, Langs G, Haggstrom I, Szczypinski P, Gibbs P, et al. Introduction to Radiomics. J Nucl Med. 2020;61(4):488–95. https://doi.org/10.2967/jnumed.118.222893.CrossRefPubMedPubMedCentral

17.

Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. https://doi.org/10.1038/ncomms5006.ADSCrossRefPubMed

18.

Lohmann P, Galldiks N, Kocher M, Heinzel A, Filss CP, Stegmayr C, et al. Radiomics in neuro-oncology: Basics, workflow, and applications. Methods. 2021;188:112–21. https://doi.org/10.1016/j.ymeth.2020.06.003.CrossRefPubMed

19.

Kocak B, Durmaz ES, Ates E, Kilickesmez O. Radiomics with artificial intelligence: a practical guide for beginners. Diagn Interv Radiol. 2019;25(6):485–95. https://doi.org/10.5152/dir.2019.19321.CrossRefPubMedPubMedCentral

20.

Hamet P, Tremblay J. Artificial intelligence in medicine. Metabolism. 2017;69:S36–S40. https://doi.org/10.1016/j.metabol.2017.01.011.CrossRef

21.

Zaharchuk G, Gong E, Wintermark M, Rubin D, Langlotz CP. Deep Learning in Neuroradiology. AJNR Am J Neuroradiol. 2018;39(10):1776–84. https://doi.org/10.3174/ajnr.A5543.CrossRefPubMedPubMedCentral

22.

Chiu YC, Zheng SY, Wang LJ, Iskra BS, Rao MK, Houghton PJ, et al. Predicting and characterizing a cancer dependency map of tumors with deep learning. Sci Adv. 2021; https://doi.org/10.1126/sciadv.abh1275.CrossRefPubMedPubMedCentral

23.

Rudie JD, Rauschecker AM, Bryan RN, Davatzikos C, Mohan S. Emerging Applications of Artificial Intelligence in Neuro-Oncology. Radiology. 2019;290(3):607–18. https://doi.org/10.1148/radiol.2018181928.CrossRefPubMed

24.

Jiang Y, Yang M, Wang S, Li X, Sun Y. Emerging role of deep learning-based artificial intelligence in tumor pathology. Cancer Commun (Lond). 2020;40(4):154–66.https://doi.org/10.1002/cac2.12012

25.

Xu J, Meng Y, Qiu K, Topatana W, Li S, Wei C, et al. Applications of Artificial Intelligence Based on Medical Imaging in Glioma: Current State and Future Challenges. Front Oncol. 2022;12:892056. https://doi.org/10.3389/fonc.2022.892056.CrossRefPubMedPubMedCentral

26.

Kim JY, Park JE, Jo Y, Shim WH, Nam SJ, Kim JH, et al. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients. Neuro Oncol. 2019;21(3):404–14. https://doi.org/10.1093/neuonc/noy133.CrossRefPubMed

27.

Park YW, Choi D, Park JE, Ahn SS, Kim H, Chang JH, et al. Differentiation of recurrent glioblastoma from radiation necrosis using diffusion radiomics with machine learning model development and external validation. Sci Rep. 2021;11(1):2913.ADSCrossRefPubMedPubMedCentral

28.

Choi Y, Nam Y, Jang J, Shin N‑Y, Lee YS, Ahn K‑J, et al. Radiomics may increase the prognostic value for survival in glioblastoma patients when combined with conventional clinical and genetic prognostic models. Eur Radiol. 2020;31(4):2084–93. CrossRefPubMed

29.

Jia X, Zhai Y, Song D, Wang Y, Wei S, Yang F, et al. A Multiparametric MRI-Based Radiomics Nomogram for Preoperative Prediction of Survival Stratification in Glioblastoma Patients With Standard Treatment. Front Oncol. 2022;12:758622. https://doi.org/10.3389/fonc.2022.758622.CrossRefPubMedPubMedCentral

30.

Xu Y, He X, Li Y, Pang P, Shu Z, Gong X. The Nomogram of MRI-based Radiomics with Complementary Visual Features by Machine Learning Improves Stratification of Glioblastoma Patients: A Multicenter Study. J Magn Reson Imaging. 2021;54(2):571–83. https://doi.org/10.1002/jmri.27536.CrossRefPubMed

31.

Su CQ, Chen XT, Duan SF, Zhang JX, You YP, Lu SS, et al. A radiomics-based model to differentiate glioblastoma from solitary brain metastases. Clin Radiol. 2021;76(8):629 e11–e18.https://doi.org/10.1016/j.crad.2021.04.012

32.

Xia W, Hu B, Li H, Shi W, Tang Y, Yu Y, et al. Deep Learning for Automatic Differential Diagnosis of Primary Central Nervous System Lymphoma and Glioblastoma: Multi-Parametric Magnetic Resonance Imaging Based Convolutional Neural Network Model. J Magn Reson Imaging. 2021;54(3):880–7. https://doi.org/10.1002/jmri.27592.CrossRefPubMed

33.

Gutta S, Acharya J, Shiroishi MS, Hwang D, Nayak KS. Improved Glioma Grading Using Deep Convolutional Neural Networks. Ajnr Am J Neuroradiol. 2021;42(2):233–9. https://doi.org/10.3174/ajnr.A6882.CrossRefPubMedPubMedCentral

34.

Lin K, Cidan W, Qi Y, Wang X. Glioma grading prediction using multiparametric magnetic resonance imaging-based radiomics combined with proton magnetic resonance spectroscopy and diffusion tensor imaging. Med Phys. 2022;49(7):4419–29. https://doi.org/10.1002/mp.15648.CrossRefPubMed

35.

Casale R, Lavrova E, Sanduleanu S, Woodruff HC, Lambin P. Development and external validation of a non-invasive molecular status predictor of chromosome 1p/19q co-deletion based on MRI radiomics analysis of Low Grade Glioma patients. Eur J Radiol. 2021;139:109678. https://doi.org/10.1016/j.ejrad.2021.109678.CrossRefPubMed

36.

Wang J, Hu Y, Zhou X, Bao S, Chen Y, Ge M, et al. A radiomics model based on DCE-MRI and DWI may improve the prediction of estimating IDH1 mutation and angiogenesis in gliomas. Eur J Radiol. 2022;147:110141. https://doi.org/10.1016/j.ejrad.2021.110141.CrossRefPubMed

37.

Wu S, Zhang X, Rui W, Sheng Y, Yu Y, Zhang Y, et al. A nomogram strategy for identifying the subclassification of IDH mutation and ATRX expression loss in lower-grade gliomas. Eur Radiol. 2022;32(5):3187–98. https://doi.org/10.1007/s00330–021–08444–1.CrossRefPubMed

38.

Xi YB, Guo F, Xu ZL, Li C, Wei W, Tian P, et al. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma. J Magn Reson Imaging. 2018;47(5):1380–7. https://doi.org/10.1002/jmri.25860.CrossRefPubMed

39.

Zhang S, Sun H, Su X, Yang X, Wang W, Wan X, et al. Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and O(6) -methylguanine-DNA methyltransferase promoter methylation in patients with gliomas. J Magn Reson Imaging. 2021;54(1):197–205. https://doi.org/10.1002/jmri.27498.CrossRefPubMed

40.

Fan X, Li J, Huang B, Lu H, Lu C, Pan M, et al. Noninvasive radiomics model reveals macrophage infiltration in glioma. Cancer Lett. 2023; https://doi.org/10.1016/j.canlet.2023.216380.CrossRefPubMed

41.

Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, et al. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer. 2022;21(1):39.CrossRefPubMedPubMedCentral

42.

Mizukoshi E, Kaneko S. Telomerase-Targeted Cancer. Immunotherapy Int J Mol Sci. 2019; https://doi.org/10.3390/ijms20081823.CrossRefPubMed

43.

Guo Y, Chen Y, Zhang L, Ma L, Jiang K, Yao G, et al. TERT Promoter Mutations and Telomerase in Melanoma. J Oncol. 2022;2022:6300329. https://doi.org/10.1155/2022/6300329.CrossRefPubMedPubMedCentral

44.

Aquilanti E, Kageler L, Wen PY, Meyerson M. Telomerase as a therapeutic target in glioblastoma. Neuro Oncol. 2021;23(12):2004–13. https://doi.org/10.1093/neuonc/noab203.CrossRefPubMedPubMedCentral

45.

Batsios G, Taglang C, Tran M, Stevers N, Barger C, Gillespie AM, et al. Deuterium Metabolic Imaging Reports on TERT Expression and Early Response to Therapy in Cancer. Clin Cancer Res. 2022;28(16):3526–36.CCR-21–4418.CrossRefPubMedPubMedCentral

46.

Fujimoto K, Arita H, Satomi K, Yamasaki K, Matsushita Y, Nakamura T, et al. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol. 2021;142(2):323–38.CrossRefPubMed

47.

Bollam SR, Berens ME, Dhruv HD. When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM. Curr Neurol Neurosci Rep. 2018;18(4):15.CrossRefPubMed

48.

Lu J, Li X, Li H. A radiomics feature-based nomogram to predict telomerase reverse transcriptase promoter mutation status and the prognosis of lower-grade gliomas. Clin Radiol. 2022;77(8):e560–e7. https://doi.org/10.1016/j.crad.2022.04.005.CrossRefPubMed

49.

Yan J, Zhang B, Zhang S, Cheng J, Liu X, Wang W, et al. Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients. Npj Precis Oncol. 2021;5(1):72.CrossRefPubMedPubMedCentral

50.

Jiang C, Kong Z, Zhang Y, Liu S, Liu Z, Chen W, et al. Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas. Neuroradiology. 2020;62(7):803–13.CrossRefPubMed

51.

Tian H, Wu H, Wu G, Xu G. Noninvasive Prediction of TERT Promoter Mutations in High-Grade Glioma by Radiomics Analysis Based on Multiparameter MRI. Biomed Res Int. 2020;2020:3872314. https://doi.org/10.1155/2020/3872314.CrossRefPubMedPubMedCentral

52.

Fukuma R, Yanagisawa T, Kinoshita M, Shinozaki T, Arita H, Kawaguchi A, et al. Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network. Sci Rep. 2019;9(1):20311. ADSCrossRefPubMedPubMedCentral

53.

Fang S, Fan Z, Sun Z, Li Y, Liu X, Liang Y, et al. Radiomics Features Predict Telomerase Reverse Transcriptase Promoter Mutations in World Health Organization Grade II Gliomas via a Machine-Learning Approach. Front Oncol. 2020;10:606741. https://doi.org/10.3389/fonc.2020.606741.CrossRefPubMed

54.

Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022;85:253–75. https://doi.org/10.1016/j.semcancer.2022.04.002.CrossRefPubMed

55.

Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi H, et al. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021;12(1):177.CrossRefPubMedPubMedCentral

56.

Ll Z, Kl X, Sw W, Bl H, Lr C. Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas. Histopathology. 2012;61(4):726–36.CrossRef

57.

Pease M, Gersey ZC, Ak M, Elakkad A, Kotrotsou A, Zenkin S, et al. Pre-operative MRI radiomics model non-invasively predicts key genomic markers and survival in glioblastoma patients. J Neurooncol. 2022;160(1):253–63.CrossRefPubMed

58.

Li Y, Liu X, Xu K, Qian Z, Wang K, Fan X, et al. MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis. Eur Radiol. 2018;28(1):356–62.CrossRefPubMed

59.

Kihira S, Tsankova NM, Bauer A, Sakai Y, Mahmoudi K, Zubizarreta N, et al. Multiparametric MRI texture analysis in prediction of glioma biomarker status: added value of MR diffusion. Neurooncol Adv. 2021;3(1):vdab51. https://doi.org/10.1093/noajnl/vdab051.CrossRefPubMedPubMedCentral

60.

Park YW, Ahn SS, Park CJ, Han K, Kim EH, Kang SG, et al. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas. Eur Radiol. 2020;30(12):6475–84.CrossRefPubMed

61.

Park YW, Park JE, Ahn SS, Kim EH, Kang SG, Chang JH, et al. Magnetic Resonance Imaging Parameters for Noninvasive Prediction of Epidermal Growth Factor Receptor Amplification in Isocitrate Dehydrogenase-Wild-Type Lower-Grade Gliomas: A Multicenter Study. Neurosurgery. 2021;89(2):257–65. https://doi.org/10.1093/neuros/nyab136.CrossRefPubMed

62.

Hedyehzadeh M, Maghooli K, MomenGharibvand M, Pistorius S. A Comparison of the Efficiency of Using a Deep CNN Approach with Other Common Regression Methods for the Prediction of EGFR Expression in Glioblastoma Patients. J Digit Imaging. 2020;33(2):391–8.CrossRefPubMed

63.

Akbari H, Bakas S, Pisapia JM, Nasrallah MP, Rozycki M, Martinez-Lage M, et al. In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature. Neuro. Oncol. 2018;20(8):1068–79. https://doi.org/10.1093/neuonc/noy033.CrossRef

64.

Seow P, Wong JHD, Ahmad-Annuar A, Mahajan A, Abdullah NA, Ramli N. Quantitative magnetic resonance imaging and radiogenomic biomarkers for glioma characterisation: a systematic review. Br J Radiol. 2018; https://doi.org/10.1259/bjr.20170930.CrossRefPubMedPubMedCentral

65.

Alhejaily A, Day AG, Feilotter HE, Baetz T, Lebrun DP. Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome. Clin. Cancer Res. 2014;20(6):1676–86.

66.

Huang LE. Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma. Biomedicines. 2022; https://doi.org/10.3390/biomedicines10020246.CrossRefPubMedPubMedCentral

67.

Tesileanu CMS, Vallentgoed WR, French PJ, van den Bent MJ. Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review. Eur J Cancer. 2022;175:214–23. https://doi.org/10.1016/j.ejca.2022.08.016.CrossRefPubMed

68.

Liu EM, Shi ZF, Li KK, Malta TM, Chung NY, Chen H, et al. Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas. Brain Pathol. 2022;32(6):e13107. https://doi.org/10.1111/bpa.13107.CrossRefPubMedPubMedCentral

69.

Calabrese E, Rudie JD, Rauschecker AM, Villanueva-Meyer JE, Clarke JL, Solomon DA, et al. Combining radiomics and deep convolutional neural network features from preoperative MRI for predicting clinically relevant genetic biomarkers in glioblastoma. Neurooncol Adv. 2022;4(1):vdac60. https://doi.org/10.1093/noajnl/vdac060.CrossRefPubMedPubMedCentral

70.

Park YW, Park KS, Park JE, Ahn SS, Park I, Kim HS, et al. Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study. Korean J Radiol. 2023;24(2):133–44. https://doi.org/10.3348/kjr.2022.0732.CrossRefPubMedPubMedCentral

71.

Śledzińska P, Bebyn MG, Furtak J, Kowalewski J, Lewandowska MA. Prognostic and Predictive Biomarkers in Gliomas. IJMS. 2021; https://doi.org/10.3390/ijms221910373.CrossRefPubMedPubMedCentral

72.

Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015;372(26):2481–98.https://doi.org/10.1056/NEJMoa1402121

73.

Berzero G, Di Stefano AL, Ronchi S, Bielle F, Villa C, Guillerm E, et al. IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro. Oncol. 2021;23(6):955–66. https://doi.org/10.1093/neuonc/noaa258.CrossRef

74.

Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN, et al. Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol. 2017;134(6):957–9.CrossRefPubMed

75.

Vermeulen C, Pagès-Gallego M, Kester L, Kranendonk MEG, Wesseling P, Verburg N, et al. Ultra-fast deep-learned CNS tumour classification during surgery. Nature. 2023;622(7984):842–9.ADSCrossRefPubMedPubMedCentral

Titel: Artificial Intelligence Imaging for Predicting High-risk Molecular Markers of Gliomas
verfasst von: Qian Liang
Hui Jing
Yingbo Shao
Yinhua Wang
Hui Zhang
Publikationsdatum: 26.01.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Neuroradiology / Ausgabe 1/2024
Print ISSN: 1869-1439
Elektronische ISSN: 1869-1447
DOI: https://doi.org/10.1007/s00062-023-01375-y

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Artificial Intelligence Imaging for Predicting High-risk Molecular Markers of Gliomas

Abstract

Neu im Fachgebiet Radiologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Klinikreform soll zehntausende Menschenleben retten

Darf man die Behandlung eines Neonazis ablehnen?

Update Radiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Improvement of Neurovascular Imaging Using Ultra-High-Resolution Computed Tomography Angiography

Reply: Diagnosis of Small Unruptured Intracranial Aneurysms: Comparison of 7 T Versus 3 T MRI

Efficacy and Safety Outcomes for Acute Ischemic Stroke Patients Treated with Intravenous Infusion of Tirofiban After Emergent Carotid Artery Stenting

Long-term Follow-up After Aneurysm Treatment with the Flow Redirection Endoluminal Device (FRED) Flow Diverter

Safety Aspects and Procedural Characteristics of Ambulatory Diagnostic Cerebral Catheter Angiography

Systematic Review and Meta-analysis of Radial or Femoral Access for Carotid Stenting

Neu im Fachgebiet Radiologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Klinikreform soll zehntausende Menschenleben retten

Darf man die Behandlung eines Neonazis ablehnen?

Update Radiologie

Reply: Diagnosis of Small Unruptured Intracranial Aneurysms: Comparison of 7 T Versus 3 T MRI